Aurinia Pharmaceuticals Inc Total Liabilities
Aurinia Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Aurinia Pharmaceuticals Inc (AUPH) has total liabilities worth $177.40 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check AUPH cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Aurinia Pharmaceuticals Inc (1998–2025)
Total liabilities of Aurinia Pharmaceuticals Inc from 1998 to 2025. This chart illustrates how Aurinia Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore AUPH long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Aurinia Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Aurinia Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SAGILITY INDIA LIMITED
NSE:SAGILITY
|
India | Rs28.62 Billion |
|
Sichuan Teway Food Group Co Ltd
SHG:603317
|
China | CN¥902.01 Million |
|
L1 Group Limited
AU:L1G
|
Australia | AU$205.86 Million |
|
China Railway Materials Co Ltd
SHE:000927
|
China | CN¥10.05 Billion |
|
Stagwell Inc
NASDAQ:STGW
|
USA | $3.49 Billion |
|
Zhuhai Bojay Electronics Co Ltd
SHE:002975
|
China | CN¥1.09 Billion |
|
Zhejiang Changsheng Sliding Bearings Co Ltd Class A
SHE:300718
|
China | CN¥275.46 Million |
|
Compania Cervecerias Unidas SA
SN:CCU
|
Chile | CL$2.03 Trillion |
Liability Composition Analysis (1998–2025)
This chart breaks down Aurinia Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see AUPH asset base.
Liquidity & Leverage Metrics
Aurinia Pharmaceuticals Inc Total Liabilities Ratios Explained
Aurinia Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aurinia Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aurinia Pharmaceuticals Inc (1998–2025)
The table below shows the annual total liabilities of Aurinia Pharmaceuticals Inc from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $170.26 Million | -1.68% |
| 2024-12-31 | $173.17 Million | +1.80% |
| 2023-12-31 | $170.11 Million | +160.00% |
| 2022-12-31 | $65.42 Million | +1.79% |
| 2021-12-31 | $64.28 Million | +14.96% |
| 2020-12-31 | $55.91 Million | +117.54% |
| 2019-12-31 | $25.70 Million | -22.79% |
| 2018-12-31 | $33.29 Million | +38.10% |
| 2017-12-31 | $24.10 Million | +14.52% |
| 2016-12-31 | $21.05 Million | +54.71% |
| 2015-12-31 | $13.60 Million | +87.07% |
| 2014-12-31 | $7.27 Million | -26.11% |
| 2013-12-31 | $9.84 Million | +56.75% |
| 2012-12-31 | $6.28 Million | -20.63% |
| 2011-12-31 | $7.91 Million | +101.05% |
| 2010-12-31 | $3.93 Million | -16.98% |
| 2009-12-31 | $4.74 Million | -74.78% |
| 2008-12-31 | $18.79 Million | +31.82% |
| 2007-12-31 | $14.25 Million | +36.12% |
| 2006-12-31 | $10.47 Million | -12.69% |
| 2005-12-31 | $11.99 Million | +33.65% |
| 2004-12-31 | $8.97 Million | +52.33% |
| 2003-12-31 | $5.89 Million | +88.80% |
| 2002-12-31 | $3.12 Million | +75.33% |
| 2001-12-31 | $1.78 Million | +47.12% |
| 2000-12-31 | $1.21 Million | +27.22% |
| 1999-12-31 | $950.74K | -60.53% |
| 1998-12-31 | $2.41 Million | -- |
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and … Read more